Robert E. Landry - 16 Nov 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
16 Nov 2021
Net transactions value
-$941,470
Form type
4
Filing time
18 Nov 2021, 15:23:06 UTC
Previous filing
01 Sep 2021
Next filing
10 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1,498,725 +3,750 +14% $399.66 29,736 16 Nov 2021 Direct F1
transaction REGN Common Stock Tax liability $2,000,896 -3,069 -10% $651.97 26,667 16 Nov 2021 Direct F1
transaction REGN Common Stock Sale $439,299 -681 -2.6% $645.08 25,986 17 Nov 2021 Direct F1
holding REGN Common Stock 229 16 Nov 2021 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -3,750 -15% $0.000000 21,250 16 Nov 2021 Common Stock 3,750 $399.66 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.